Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents of Enliven Therapeutics, Inc. from 31 Dec 2018 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Summary
Enliven Therapeutics, Inc. quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents in USD history and change rate from 31 Dec 2018 to 31 Dec 2025.
  • Enliven Therapeutics, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents for the quarter ending 31 Dec 2025 was $98,896,000, a 20% decline year-over-year.
Source SEC data
View on sec.gov
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Quarterly (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, YoY Quarterly Change (%)

Enliven Therapeutics, Inc. Quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $98,896,000 -$25,275,000 -20% 31 Dec 2025 10-K 03 Mar 2026 2025 FY
Q3 2025 $101,732,000 +$1,057,000 +1% 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 $119,437,000 +$22,512,000 +23% 30 Jun 2025 10-Q 13 Aug 2025 2025 Q2
Q1 2025 $101,705,000 -$47,514,000 -32% 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q4 2024 $124,171,000 +$23,976,000 +24% 31 Dec 2024 10-K 03 Mar 2026 2025 FY
Q3 2024 $100,675,000 +$26,774,000 +36% 30 Sep 2024 10-Q 12 Nov 2025 2025 Q3
Q2 2024 $96,925,000 -$28,844,000 -23% 30 Jun 2024 10-Q 13 Aug 2025 2025 Q2
Q1 2024 $149,219,000 -$142,937,000 -49% 31 Mar 2024 10-Q 14 May 2025 2025 Q1
Q4 2023 $100,195,000 +$24,605,000 +33% 31 Dec 2023 10-K 03 Mar 2026 2025 FY
Q3 2023 $73,901,000 -$12,312,000 -14% 30 Sep 2023 10-Q 13 Nov 2024 2024 Q3
Q2 2023 $125,769,000 +$33,259,000 +36% 30 Jun 2023 10-Q 13 Aug 2024 2024 Q2
Q1 2023 $292,156,000 +$192,224,000 +192% 31 Mar 2023 10-Q 14 May 2024 2024 Q1
Q4 2022 $75,590,000 -$34,488,000 -31% 31 Dec 2022 10-K 13 Mar 2025 2024 FY
Q3 2022 $86,213,000 +$10,743,000 +14% 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $92,510,000 +$44,298,000 +92% 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 $99,932,000 +$46,403,000 +87% 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $110,078,000 -$20,341,000 -16% 31 Dec 2021 10-K 14 Mar 2024 2023 FY
Q3 2021 $75,470,000 +$41,224,000 +120% 30 Sep 2021 10-Q 25 Oct 2022 2022 Q3
Q2 2021 $48,212,000 -$6,527,000 -12% 30 Jun 2021 10-Q 03 Aug 2022 2022 Q2
Q1 2021 $53,529,000 -$33,281,000 -38% 31 Mar 2021 10-Q 06 May 2022 2022 Q1
Q4 2020 $130,419,000 +$125,395,000 +2496% 31 Dec 2020 8-K 23 Jun 2023
Q3 2020 $34,246,000 +$17,072,000 +99% 30 Sep 2020 10-Q 09 Nov 2021 2021 Q3
Q2 2020 $54,739,000 +$9,418,000 +21% 30 Jun 2020 10-Q 06 Aug 2021 2021 Q2
Q1 2020 $86,810,000 +$37,908,000 +78% 31 Mar 2020 10-Q 11 May 2021 2021 Q1
Q4 2019 $5,024,000 -$2,358,000 -32% 31 Dec 2019 10-K 15 Mar 2022 2021 FY
Q3 2019 $17,174,000 30 Sep 2019 10-Q 05 Nov 2020 2020 Q3
Q2 2019 $45,321,000 30 Jun 2019 10-Q 14 Aug 2020 2020 Q2
Q1 2019 $48,902,000 31 Mar 2019 10-Q 07 May 2020 2020 Q1
Q4 2018 $7,382,000 31 Dec 2018 10-K 05 Mar 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.